Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The cholesterol and recurrent events trial (CARE)

1991 ◽  
Vol 68 (15) ◽  
pp. 1436-1446 ◽  
Author(s):  
Frank M. Sacks ◽  
Marc A. Pfeffer ◽  
Lemuel Moye' ◽  
Lisa E. Brown ◽  
Peggy Hamm ◽  
...  
1995 ◽  
Vol 76 (9) ◽  
pp. 98C-106C ◽  
Author(s):  
Marc A. Pfeffer ◽  
Frank M. Sacks ◽  
Lemuel A. Moyé ◽  
Lisa Brown ◽  
Jean L. Rouleau ◽  
...  

PEDIATRICS ◽  
1976 ◽  
Vol 58 (2) ◽  
pp. 211-217
Author(s):  
Charles H. Hennekens ◽  
Mary Jane Jesse ◽  
Barbara E. Klein ◽  
Janet E. Gourley ◽  
Sidney Blumenthal

Plasma cholesterol levels were obtained on 90 children of 39 men with premature myocardial infarction and 86 children of 39 healthy men. The mean cholesterol among children of affected men (195.1 mg/100 ml) was higher than among children of healthy men (176.6 mg/100 ml) (P = .009). Higher mean levels were demonstrable at each of nine age groups from 1 to 21 years (P = .004). Levels greater than 230 mg/100 ml were found in 16.7% of children of affected fathers and 4.7% of children of healthy fathers, a ratio of 3.6 to 1 (P = .01). These findings are compatible with the hypothesis that elevated childhood cholesterol level offers a mechanism whereby family history predicts coronary disease. A dip in cholesterol during adolescence, a finding that varies with population studied, was demonstrable among children of both affected and healthy men.


Cardiology ◽  
2018 ◽  
Vol 141 (2) ◽  
pp. 88-97 ◽  
Author(s):  
Yan Gao ◽  
Yan Qiu ◽  
Jihua Wu ◽  
Wei Diao ◽  
Haibo Zhang ◽  
...  

Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising target for lowering plasma low-density lipoprotein cholesterol and preventing cardiovascular (CV) disease. Whether plasma PCSK9 measured during the acute phase predicts recurrent CV events in patients with acute myocardial infarction (AMI) remains unresolved. Methods and Results: Plasma PCSK9 levels were measured in 1,646 patients with AMI from the China PEACE-Prospective AMI Study at the acute phase. Additionally, 248 patients were resampled and measured at 1 month post-AMI. Associations of acute-phase PCSK9 tertiles with clinical characteristics and recurrent CV events within 1 year were assessed. Female gender (OR 1.94, 95% CI 1.24–3.03), premature coronary heart disease (CHD; OR 2.12, 95% CI 1.37–3.26), higher high-sensitivity C-reactive protein (OR 1.67, 95% CI 1.44–1.95), and higher triglycerides (OR 1.46, 95% CI 1.03–2.09) were associated with higher baseline PCSK9. Plasma PCSK9 levels in the highest tertile (versus lowest) did not have an increased risk of 1-year recurrent CV events in the AMI cohort (HR 0.78, 95% CI 0.52–1.16) or any subgroup. There was also no association between percentage changes in PCSK9 over the first month and 1-year recurrent events, although there was a trend of differences between patients in the upper versus lower tertiles. Conclusion: Plasma PCSK9 levels measured during the acute phase were associated with high-sensitivity C-reactive protein, triglycerides, premature CHD, and gender in patients with AMI but did not predict recurrent CV events within 1 year. Dynamic changes in PCSK9 suggested a trend yet no significance value in predicting recurrent CV events.


Sign in / Sign up

Export Citation Format

Share Document